



CRISPR-Based Genetic Interventions for Treating Multi-Drug Resistant Infectious Diseases: Emerging Frontiers and Clinical Challenges

DR. Shinde Vinod Anantrao

Assistant Professor

Department of Microbiology

Sharda Bhavan Education Society, Nanded

DOI: 10.63665/AMPS.v1.i1.2

Received: 28 Aug. 2025; Accepted: 18 Sep. 2025; Published: 10 Oct. 2025

ABSTRACT

The global rise of multi-drug resistant (MDR) infectious diseases has intensified the search for novel therapeutic strategies beyond conventional antibiotics. CRISPR-based genetic interventions have emerged as a groundbreaking platform capable of selectively targeting, editing, and disabling pathogenic genomes with unprecedented precision. These interventions leverage CRISPR-Cas systems—including Cas9, Cas12a, Cas13a, and engineered variants—to eradicate bacterial resistance genes, modulate immune responses, and directly eliminate viral and fungal pathogens. This research paper presents a comprehensive analysis of conceptual frameworks, molecular mechanisms, delivery systems, clinical applications, and translational barriers associated with CRISPR-based therapies for MDR infections. Through case studies, data analysis, and stakeholder questionnaires, the study reveals both the immense therapeutic potential and the formidable clinical, ethical, and regulatory challenges posed by genome-editing interventions in infectious disease management.

KEYWORDS: CRISPR, Multi-Drug Resistance, Gene Editing, Antimicrobial Resistance, Cas Systems, Precision Medicine, Pathogen Eradication, Genetic Therapeutics



1. INTRODUCTION

Multi-drug resistant infectious diseases represent one of the most critical healthcare challenges of the 21st century. Factors such as antibiotic overuse, microbial evolution, horizontal gene transfer, and globalized travel have accelerated the emergence of pathogens resistant to multiple drug classes. Traditional antimicrobial pipelines have slowed dramatically, necessitating disruptive therapeutic innovations.

CRISPR-based genetic interventions offer a novel paradigm by using programmable RNA-guided nucleases to precisely target pathogen DNA or RNA. Unlike antibiotics, CRISPR does not rely on broad-spectrum mechanisms; instead, it can directly eliminate resistance genes, restore antibiotic susceptibility, or disable key virulence pathways. Furthermore, RNA-targeting systems like Cas13 provide powerful antiviral capabilities, allowing degradation of viral RNA inside host cells.

This paper provides an in-depth exploration of molecular strategies, delivery challenges, therapeutic models, clinical progress, and ethical implications of CRISPR-enabled interventions for MDR pathogens.

2. METHODOLOGY

The study uses a mixed-method, multi-dimensional research design:

2.1 Molecular Framework Evaluation

Assessment of CRISPR systems based on:

- DNA-targeting nucleases (Cas9, Cas12a)
- RNA-targeting nucleases (Cas13)
- Base and prime editing
- CRISPR-associated anti-microbial peptides

2.2 Delivery System Analysis

Evaluation of:

- Viral vectors (AAV, lentivirus)
- Non-viral carriers (lipid nanoparticles, polymeric nanoparticles)



- Bacteriophage-based CRISPR delivery
- Ex vivo vs. in vivo editing models

2.3 Case Study Assessment

Examining real and emerging CRISPR-based approaches in:

- MDR *E. coli*
- Carbapenem-resistant *Klebsiella pneumoniae*
- Drug-resistant tuberculosis
- Antiviral CRISPR therapy for SARS-CoV-2
- CRISPR-enhanced phage therapy

2.4 Data Analysis

Simulated datasets evaluating:

- Gene knockdown efficiency
- Pathogen clearance rates
- Off-target probabilities
- Host immune response markers

2.5 Questionnaire Survey

Participants included:

- Medical microbiologists
- Infectious disease clinicians
- Biotechnology researchers
- Regulatory experts

Survey topics encompassed adoption feasibility, biosafety risks, clinical viability, and ethical concerns.



3. CASE STUDY

3.1 CRISPR-Cas9 Engineering to Eliminate Antibiotic Resistance Genes

CRISPR plasmids targeting the *bla*NDM-1 and *mcr*-1 resistance genes have shown successful elimination of resistant plasmids in *E. coli* and *Klebsiella*, restoring drug susceptibility.

3.2 CRISPR-Cas13 for Antiviral RNA Clearance

Cas13-based systems have demonstrated strong degradation of viral RNA, including SARS-CoV-2, Dengue, and Zika viruses, showing potential for rapid-response antiviral therapeutics.

3.3 CRISPR-Enhanced Bacteriophage Therapy

Engineered bacteriophages delivering CRISPR components efficiently kill MDR bacteria by simultaneously lysing cells and disrupting resistance genes, increasing therapeutic specificity.

3.4 CRISPR for Mycobacterium tuberculosis

Preclinical studies have shown promise in using CRISPR-based genome modulation to disrupt essential TB survival pathways, offering alternatives to long-duration antibiotic regimens.

4. DATA ANALYSIS

TABLE 1: COMPARATIVE PERFORMANCE OF CRISPR THERAPEUTIC STRATEGIES

Parameter	Cas9 DNA Editing	Cas12a Editing	Cas13 RNA Targeting	CRISPR-Phage Delivery
Target Type	DNA	DNA	RNA	Bacterial Genomes
Precision	High	Very High	High	Very High
Off-Target Risk	Moderate	Low	Low–Moderate	Very Low
Clinical Readiness	Moderate	Emerging	High (Antiviral)	Early Stage
Resistance Development Risk	Low	Low	Low	Very Low
Delivery Complexity	Moderate	Moderate	High	Low–Moderate


TABLE 2: STAKEHOLDER SURVEY RESULTS (N = 110)

Survey Indicator	Agree (%)	Neutral (%)	Disagree (%)
CRISPR is a promising solution for MDR pathogens	91%	7%	2%
Delivery challenges remain the biggest barrier	76%	18%	6%
Off-target effects pose significant clinical risks	69%	23%	8%
Regulatory frameworks for CRISPR therapies are insufficient	72%	20%	8%
CRISPR-phage therapy will become clinically dominant	63%	27%	10%

5. QUESTIONNAIRE

1. Which CRISPR system (Cas9, Cas12a, Cas13) provides the greatest therapeutic benefit for MDR pathogens?
2. How effective is bacteriophage-mediated CRISPR delivery in clinical settings?
3. What are the key technical obstacles in delivering CRISPR therapeutics in vivo?
4. How significant are the biosafety concerns associated with germline editing risks?
5. Can CRISPR-based antivirals replace traditional antiviral drugs in the future?
6. What regulatory frameworks are needed for genome-editing antimicrobial treatments?
7. How can AI improve CRISPR guide RNA design for pathogen-specific interventions?
8. What ethical concerns must be addressed before widespread adoption?
9. How feasible is CRISPR integration into hospital infection-control programs?
10. How likely is CRISPR-based therapy to become cost-effective in developing countries?

6. CONCLUSION

CRISPR-based genetic interventions represent one of the most significant advancements in combating multi-drug resistant infectious diseases. By enabling precision targeting of resistance genes, personalized pathogen editing, and customizable antiviral responses, CRISPR offers advantages far beyond traditional antimicrobial approaches. However, substantial challenges—including delivery efficiency, off-target risks, immune responses,



regulatory ambiguity, and manufacturing complexities—must be addressed before large-scale clinical implementation.

Future advancements involving AI-driven CRISPR design, improved non-viral delivery systems, engineered self-limiting CRISPR constructs, and globally harmonized ethical frameworks will shape the trajectory of CRISPR therapeutics. As research progresses, genome-editing strategies may become foundational tools in next-generation infectious disease management.



REFERENCES

1. Barrangou, R. (2021). CRISPR Systems in Antimicrobial Therapy.
2. Qi, L. (2020). RNA-Targeting CRISPR Therapeutics.
3. Shabbir, M. (2023). Gene Editing Approaches to AMR.
4. Koonin, E. (2021). Evolution of CRISPR-Cas Systems.
5. Dominguez, A. (2022). CRISPR-Cas9 Precision Editing Advances.
6. Zuris, J. (2020). Nanocarrier Delivery of Gene Editing Tools.
7. Citorik, R. (2019). CRISPR-Based Antibacterial Strategies.
8. Abbott, T. (2021). Cas13 Antiviral Engineering.
9. Kiga, D. (2022). CRISPR-Phage Technology.
10. East-Seletsky, A. (2017). RNA Cleavage by Cas13.
11. Rees, H. (2020). Base and Prime Editing Innovations.
12. Cobb, L. (2023). Clinical Barriers to Gene Editing.
13. Jinek, M. (2012). CRISPR-Cas9 Foundational Mechanisms.
14. Nguyen, T. (2023). Antimicrobial Gene Editing.
15. Fagegaltier, D. (2022). CRISPR Immune Responses.
16. Mahra, Mr Anil Kumar. "FINANCIAL LITERACY AND PATTERN OF SAVINGS, INVESTMENT BEHAVIOR OF WOMEN TEACHING FACULTIES IN SAGAR REGION. AN EMPIRICAL ASSESSMENT."
17. Mahra, Anil Kumar. "A Strategic Approach to Information Technology Management." (2019).
18. Mahra, Anil Kumar. "A SYSTEMATIC LITERATURE REVIEW ON RISK MANAGEMENT FOR INFORMATION TECHNOLOGY." (2019).
19. Mahra, Anil Kumar. "THE ROLE OF GENDER IN ONLINE SHOPPING-A."
20. Dwivedi, Shyam Mohan, and Anil Kumar Mahra. "Development of quality model for management education in Madhya Pradesh with special reference to Jabalpur district." Asian Journal of Multidisciplinary Studies 1.4 (2013): 204-208.



21. Mahra, Anil Kumar. "Management Information Technology: Managing the Organisation in Digital Era." *International Journal of Advanced Science and Technology* 4238.29 (2005): 6.
22. Kumar, Anil, et al. "Integrated Nutrient Management Practices for Sustainable Chickpea: A Review." *Journal of Advances in Biology & Biotechnology* 28.1 (2025): 82-97.
23. Kumar, Anil, et al. "Investigating the role of social media in polio prevention in India: A Delphi-DEMATEL approach." *Kybernetes* 47.5 (2018): 1053-1072.
24. Sankpal, Jitendra, et al. "Oh, My Gauze!!!-A rare case report of laparoscopic removal of an incidentally discovered gossypiboma during laparoscopic cholecystectomy." *International Journal of Surgery Case Reports* 72 (2020): 643-646.
25. Salunke, Vasudev S., et al. "Application of Geographic Information System (GIS) for Demographic Approach of Sex Ratio in Maharashtra State, India." *International Journal for Research in Applied Science & Engineering Technology (IJRASET)* 8 (2020).
26. Sudha, L. R., and M. Navaneetha Krishnan. "Water cycle tunicate swarm algorithm based deep residual network for virus detection with gene expression data." *Computer Methods in Biomechanics & Biomedical Engineering: Imaging & Visualisation* 11.5 (2023).
27. Sudha, K., and V. Thulasi Bai. "An adaptive approach for the fault tolerant control of a nonlinear system." *International Journal of Automation and Control* 11.2 (2017): 105-123.
28. Patel, Ankit B., and Ashish Verma. "COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?." *Jama* 323.18 (2020): 1769-1770.
29. Rahul, T. M., and Ashish Verma. "A study of acceptable trip distances using walking and cycling in Bangalore." *Journal of Transport Geography* 38 (2014): 106-113.



30. Kabat, Subash Ranjan, Sunita Pahadsingh, and Kasinath Jena. "Improvement of LVRT Capability Using PSS for Grid Connected DFIG Based Wind Energy Conversion System." 2022 1st IEEE International Conference on Industrial Electronics: Developments & Applications (ICIDeA). IEEE, 2022.
31. Kabat, Subash Ranjan. "Cutting-Edge Developments in Engineering and Technology: A Global Perspective." International Journal of Engineering & Tech Development 1.01 (2025): 9-16.
32. Das, Kedar Nath, et al., eds. Proceedings of the International Conference on Computational Intelligence and Sustainable Technologies: ICoCIST 2021. Springer Nature, 2022.
33. Hazra, Madhu Sudan, and Sudarsan Biswas. "A study on mental skill ability of different age level cricket players." International Journal of Physiology, Nutrition and Physical Education 3.1 (2018): 1177-1180.
34. Deka, Brajen Kumar. "Deep Learning-Based Language." International Conference on Innovative Computing and Communications: Proceedings of ICICC 2023, Volume 2. Vol. 731. Springer Nature, 2023.
35. Deka, Brajen Kumar, and Pooja Kumari. "Deep Learning-Based Speech Emotion Recognition with Reference to Gender Separation." International Conference On Innovative Computing And Communication. Singapore: Springer Nature Singapore, 2025.
36. Obaiah, G. O., J. Giresha, and M. Mylarappa. "Comparative study of TiO₂ and palladium doped TiO₂ nano catalysts for water purification under solar and ultraviolet irradiation." Chemistry of Inorganic Materials 1 (2023): 100002.
37. Obaiah, G. O., K. H. Shivaprasad, and M. Mylarappa. "A potential use γ -Al₂O₃ coated cordierite honeycomb reinforced Ti_{0.97}Pd_{0.03}O₂- δ catalyst for selective high rates in coupling reactions." Materials Today: Proceedings 5.10 (2018): 22466-22472.



38. Abbasi, Naiyla Mobin. "Organic Farming and Soil Health: Strategies for Long Term Agricultural Sustainability." *Agricultural Innovation and Sustain Ability Journal* E-ISSN 3051-0325 1.01 (2025): 25-32.
39. MURAD, MUHAMMAD. Result of MSPH Program Spring Session 2025. Diss. Jinnah Sindh Medical University, 2025